Sydney, Australia 31 March 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results from the Co-PSMA (NCT06907641)1 investigator-initiated trial (IIT) are now published in European Urology2, the official journal of…
Sydney, Australia 10 March 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III AMPLIFY trial (NCT06970847)1 has now consented in excess of the planned number of participants following strong…
Sydney, Australia 23 February 2026 Highlights Another participant with metastatic castration-resistant prostate cancer (mCRPC) in the Cohort Expansion Phase (Phase II; 8 GBq of 67Cu-SAR-bisPSMA per cycle) of the SECuRE trial (NCT04868604)1 achieved undetectable disease as assessed by prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET). Undetectable disease by PSA was…
Sydney, Australia 16 February 2026 Highlights Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. The study was led by Prof Louise Emmett at St Vincent’s Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026. Co-PSMA IIT evaluated the performance…
Sydney, Australia 17 June 2025 Highlights Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for 64Cu-SAR-bisPSMA. SpectronRx’s facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and 64Cu-SAR-bisPSMA under one roof and enables distribution to all 50 states. SpectronRx will expand current production to up to 400,000 patient-ready doses of 64Cu-SAR-bisPSMA…
Sydney, Australia 13 June 2025 Highlights Topline data from Clarity’s diagnostic Phase II trial, SABRE, showed that 64Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on standard-of-care (SOC) scans, including prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET). SAR-Bombesin targets the gastrin-releasing…
Sydney, Australia 17 April 2025 Highlights Clarity has signed a commercial-scale agreement with Nusano, Inc. (“Nusano”) for supply of copper-64 (Cu-64 or 64Cu) isotope. The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capacity, which translates into more…
Sydney, Australia 17 April 2025 Highlights Clarity received an $11,146,204 Research and Development (R&D) Tax Incentive refund, inclusive of interest, as part of the Australian Federal Government’s R&D Tax Incentive program. The receipt of the $11.1 million will provide additional funding to further the development of Clarity’s Targeted Copper Theranostic (TCT) platform of products for…
Sydney, Australia 15 April 2025 Highlights The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee (SRC) after the successful completion of the Dose Escalation Phase…
Sydney, Australia 18 November 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is…